Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases.

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid ...

Novo Nordisk's blockbuster weight loss drug semaglutide failed to slow Alzheimer's progression in trials. The studies had ...